Header Logo

Connection

STEVEN I SHERMAN to Clinical Protocols

Back to Details
This is a "connection" page, showing publications STEVEN I SHERMAN has written about Clinical Protocols.
STEVEN I SHERMAN
Connection Strength
0.020
Clinical Protocols
  1. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer. 2011 Aug 11; 11:349.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.